The majority of analysts think that the relatively high pricing of Ascletis’ IPO heavily contributed ... They also indicated that the Chinese biotech’s debut in Hong Kong coincided with ...

Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 ...

Singapore biotech firm MiRXES ... as it advises on about 40% of the listings in the current Hong Kong IPO pipeline. Jingtian has led on that front for the past few years and it is not letting ...

Antibody-drug conjugate developer Duality Biotherapeutics Inc. is gearing up for a second IPO attempt this year, having filed on Feb. 27 a new prospectus on the Hong Kong Stock Exchange. Two other ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

In the recently released 2025-2026 Budget, the Hong Kong Government has mentioned that it will further strengthen the city’s role as a leading international financial centre. It extends various ...

“It’s like leading an orchestra,” says Jiang, who coordinates a team of scientists, medical manufacturing experts, engineers and clinicians at the Hong Kong Institute of Biotechnology ...

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more ...

Based on the offer price, the total size of the IPO is expected to be 3.45 billion Hong Kong dollars, equivalent to US$443.7 million. Mixue is entering the Hong Kong IPO market at a time when ...

Existing backers include Warburg Pincus, US biotech investor OrbiMed Advisors ... Insilico has filed for a Hong Kong IPO twice, in 2023 and again in 2024, though in both cases it let those ...